Mounjaro vs Ozempic: Which Weight Loss Medication Is Right for You?

The Quick Version

Mounjaro produces more weight loss than Ozempic. That's not an opinion — it's the result of a head-to-head clinical trial published in the New England Journal of Medicine. In the SURMOUNT-5 study, patients on Mounjaro (tirzepatide) lost 20.2% of their body weight versus 13.7% for those on semaglutide (the drug in Ozempic and Wegovy) over 72 weeks.

But "which one loses more weight" isn't the same question as "which one is right for me." Insurance coverage, cost, side effects, your medical history, and how your body responds all shape the answer. Some people do better on Ozempic. Some can only get Mounjaro covered. Some switch from one to the other. This guide breaks down everything that actually matters for making that decision with your provider.

For a version of this comparison using generic names (tirzepatide vs semaglutide), the full clinical breakdown goes deeper into the science. This post focuses on the brand-name decision most patients are actually facing.

How They Work: One Receptor vs Two

Both Mounjaro and Ozempic belong to a class of drugs that mimic gut hormones to reduce appetite, slow stomach emptying, and improve blood sugar control. The difference is how many hormones they mimic.

Ozempic contains semaglutide, a GLP-1 receptor agonist. It targets one hormone pathway — glucagon-like peptide-1. When you inject Ozempic, your brain gets stronger satiety signals, your stomach empties slower after meals, and your insulin response improves. One mechanism, three effects.

Mounjaro contains tirzepatide, a dual GIP/GLP-1 receptor agonist. It does everything Ozempic does through the GLP-1 pathway, then adds activation of a second hormone receptor — GIP (glucose-dependent insulinotropic polypeptide). GIP appears to enhance fat metabolism and improve how your body handles nutrients after eating. Researchers are still sorting out exactly why the second pathway leads to more weight loss, but the clinical results are consistent across multiple trials.

Think of it as pulling one lever versus two. Both levers reduce hunger and improve metabolism. Adding the second one produces a measurably larger effect. For a deeper explanation of the dual mechanism, the tirzepatide guide goes into the biology.

Weight Loss Results: What the Trials Show

This is the data most people are looking for. We now have three important data sets.

Ozempic/Wegovy (Semaglutide) — STEP Trials

The STEP program tested semaglutide 2.4 mg (the Wegovy dose) in patients with overweight or obesity. Note: Ozempic's highest approved dose is 2 mg (for diabetes), while Wegovy goes to 2.4 mg for weight management. The weight loss numbers below are from the Wegovy dose.

• STEP 1: 14.9% average body weight loss at 68 weeks. About 86% of patients lost at least 5%, and roughly one-third lost 20% or more.
• STEP 3 (with intensive lifestyle intervention): 16% average weight loss at 68 weeks.
• STEP 5 (two-year data): Weight loss was maintained through 104 weeks on continued treatment.

In March 2026, the FDA approved Wegovy HD at 7.2 mg, which showed 20.7% average weight loss in the STEP UP trial. This brings semaglutide's weight loss potential closer to tirzepatide, but at a substantially higher milligram dose and with increased side effects. More on that in the semaglutide dosing chart.

Mounjaro/Zepbound (Tirzepatide) — SURMOUNT Trials

The SURMOUNT program tested tirzepatide at three dose levels.

• SURMOUNT-1: Average weight loss of 15% (5 mg), 19.5% (10 mg), and 20.9% (15 mg) at 72 weeks. At the two higher doses, nearly 60% of participants lost 20% or more.
• SURMOUNT-2 (patients with type 2 diabetes): Average weight loss of 12.8% (10 mg) and 14.7% (15 mg) — lower than SURMOUNT-1, which is typical because patients with diabetes tend to lose less on these drugs.

The Head-to-Head: SURMOUNT-5

This is the trial that settles the comparison. Published in the New England Journal of Medicine in May 2025, SURMOUNT-5 randomized 751 adults with obesity (without type 2 diabetes) to receive either maximum-tolerated tirzepatide (10 or 15 mg) or maximum-tolerated semaglutide (1.7 or 2.4 mg) for 72 weeks.

Outcome	Tirzepatide	Semaglutide
Mean weight loss	20.2%	13.7%
Mean pounds lost	50.3 lbs	33.1 lbs
Patients losing ≥10%	82.8%	68.2%
Patients losing ≥20%	53.3%	26.6%
Patients losing ≥25%	31.6%	16.1%
Waist circumference reduction	18.4 cm	13.0 cm

The gap is significant: a 6.5 percentage point difference in mean weight loss, with twice as many tirzepatide patients reaching the 25% threshold. This is the strongest evidence we have for a direct comparison, and it clearly favors tirzepatide.

For those keeping score at home, the new Wegovy HD 7.2 mg dose (not available when SURMOUNT-5 was conducted) may narrow this gap — but there's no head-to-head trial yet comparing the higher semaglutide dose to tirzepatide.

Side Effects: How They Compare

Both drugs share the same core side effects because both activate GLP-1 receptors and slow gastric emptying. The difference is in degree and in how well patients tolerate them.

Common Side Effects (Both Drugs)

• Nausea (most common, especially during dose escalation)
• Diarrhea
• Constipation
• Vomiting
• Abdominal pain
• Decreased appetite (desired effect, not technically a "side effect")

Where They Differ

The SURMOUNT-5 trial included a notable finding on tolerability: 5.6% of semaglutide patients discontinued due to side effects, versus 2.7% of tirzepatide patients. This runs counter to what many people expect — the "stronger" drug actually caused fewer dropouts. The likely explanation is that tirzepatide's titration schedule, with its 2.5 mg increments and transitional doses, gives the body more gradual exposure than semaglutide's titration steps.

Across the broader trial programs, GI side effects occur at roughly similar rates for both drugs. The semaglutide side effects guide covers what to expect in detail. Much of that guidance — eating smaller meals, avoiding greasy foods, staying hydrated — applies equally to tirzepatide.

Both drugs carry the same boxed warning about thyroid C-cell tumors observed in rodent studies (though this hasn't been confirmed in humans). Neither should be used in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

If you're concerned about specific interactions with other medications you take, the drug interaction checker covers both drugs.

Cost in 2026: The Real Difference

Cost is often the deciding factor, and pricing has shifted significantly in 2026. Here's the current picture.

List Price

	Mounjaro	Ozempic
Monthly list price	~$1,080	~$998
Annual list price	~$12,960	~$11,976

At list price, the difference is minimal — roughly $80/month. But almost nobody pays list price.

With Insurance

For type 2 diabetes, both Mounjaro and Ozempic are widely covered by commercial insurance plans. Co-pays typically range from $25-$150/month depending on your plan's formulary tier and whether you use manufacturer savings cards.

For weight loss (the off-label use case for Ozempic, or the on-label use case for their weight-loss counterparts Zepbound and Wegovy), coverage varies dramatically by plan. As of April 2026, Medicare now covers Zepbound, which has expanded access for a large patient population. Many employer-sponsored plans still exclude weight loss medications, though that's changing as the economic case for coverage improves.

The insurance coverage guide has a detailed breakdown by plan type, including new 2026 coverage changes. The cost calculator can estimate your out-of-pocket cost based on your specific insurance.

Cash Pay / Self-Pay

This is where significant differences emerge. Novo Nordisk has introduced direct-to-patient pricing for semaglutide products that undercuts Eli Lilly's cash-pay options. Manufacturer discount programs, GoodRx coupons, and pharmacy negotiation all affect the real number. Some patients pay $300-$500/month through telehealth providers or discount programs. The telehealth guide covers where to find competitive cash-pay pricing.

For patients exploring alternatives, compounded versions of both drugs have been available through some peptide clinics, though the legal and regulatory status of compounded GLP-1 medications has been a moving target. The peptide therapy cost guide covers this in more detail.

The Bottom Line on Cost

If insurance covers one but not the other, that typically makes the decision for you. If both are covered equally, the clinical data favors Mounjaro. If you're paying cash, Ozempic/Wegovy may be cheaper depending on the specific deal you can find — but you should run the numbers for your situation rather than assuming.

Dosing Comparison: What the Schedule Looks Like

Both drugs are injected once weekly. Both require slow titration to reduce side effects. The specifics differ.

Feature	Mounjaro (Tirzepatide)	Ozempic (Semaglutide)
Starting dose	2.5 mg	0.25 mg
Dose steps	2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg	0.25 → 0.5 → 1 → 2 mg
Increment pattern	2.5 mg steps	Irregular (doubles, then varies)
Time at each step	4 weeks minimum	4 weeks minimum
Maintenance doses	5, 10, or 15 mg	0.5, 1, or 2 mg
Maximum dose	15 mg	2 mg (Ozempic) / 2.4 mg (Wegovy) / 7.2 mg (Wegovy HD)
Time to max dose	~20 weeks	~8 weeks (Ozempic) / ~16 weeks (Wegovy)
Pen type	Multi-dose KwikPen (4 doses per pen)	Single-dose prefilled pen
Oral option	Not available	Yes — oral Wegovy 50 mg daily

The tirzepatide dosing chart and semaglutide dosing chart each have the full titration schedules with detailed guidance on what to expect at each level.

A practical note: Mounjaro's KwikPen holds four weekly doses in one device. You attach a new needle each week and inject from the same pen for a month. Ozempic uses a multi-dose pen as well, but Wegovy uses single-dose pens — one injection per device. The actual injection technique is the same subcutaneous process for both. If you're new to self-injection, the injection guide covers the basics.

Who Is Mounjaro Better For?

Based on clinical data, Mounjaro may be the stronger choice in these situations:

You want maximum weight loss. The data is clear — tirzepatide produces more weight loss than semaglutide at maximum doses. If your primary goal is losing the most weight possible, and cost/insurance aren't barriers, the clinical evidence points to Mounjaro (or Zepbound for the weight management indication).

You have type 2 diabetes and want weight loss. Mounjaro is FDA-approved for diabetes and shows excellent blood sugar control alongside weight loss. It may allow your provider to address both conditions with a single medication.

You're sensitive to GI side effects. Counterintuitively, tirzepatide's slower, more gradual titration (six dose steps vs four for Wegovy) and lower discontinuation rate in SURMOUNT-5 suggest it may be easier to tolerate for some patients.

You've plateaued on Ozempic. Switching from semaglutide to tirzepatide is a common move when patients stop losing weight on Ozempic. The added GIP pathway can restart weight loss for some people. This is something to discuss with your provider.

Who Is Ozempic Better For?

Ozempic may be the better fit in these circumstances:

Your insurance covers Ozempic but not Mounjaro. Formulary placement matters. If your plan has Ozempic on a preferred tier and Mounjaro on a higher tier or excluded entirely, the cost difference can be hundreds of dollars per month.

You prefer an oral option. Semaglutide is the only GLP-1 available as a once-daily pill. Oral Wegovy launched in January 2026 and eliminates the need for weekly injections. Tirzepatide has no oral formulation.

You want the most established safety record. Semaglutide has been on the market longer and has more long-term safety data. Both drugs appear safe based on current evidence, but some patients and providers are more comfortable with the longer track record.

You don't need maximum weight loss to reach your goals. If your target is 10-15% body weight loss, semaglutide gets most people there. You don't necessarily need the extra 5-7 percentage points tirzepatide provides if a smaller loss meets your health goals.

Cost is the primary factor. Depending on your insurance and available discounts, semaglutide products may be more affordable than tirzepatide in your specific situation.

A Practical Decision Framework

Instead of asking "which is better," try asking these questions with your provider:

1. What does my insurance cover? Check both drugs. Call your pharmacy benefits manager. The answer often narrows the field immediately. The insurance guide can help you understand what to ask.

2. What are my weight loss goals? Be specific. Losing 10% of body weight for metabolic health is a different goal than losing 25% for mobility or surgical preparation. The weight loss calculator can show you projected outcomes for each drug.

3. How do I feel about injections long-term? If the needle is a barrier, semaglutide's oral option gives you an exit from injections down the road.

4. What's my medical history? Both drugs have contraindications. History of pancreatitis, medullary thyroid cancer, or gallbladder disease all factor in. Your provider should review this before prescribing either one.

5. What has my provider seen work? Clinicians who prescribe both drugs regularly develop an intuition for which patients do better on which medication. Their experience matters. If you don't have a provider with this experience, the provider matching quiz connects you with clinicians who prescribe both Mounjaro and Ozempic regularly.

Can You Switch Between Mounjaro and Ozempic?

Yes, and it's common. Patients switch for several reasons: insurance changes, side effect tolerance, plateaued weight loss, or simply trying the other option. There's no required washout period between the two drugs — your provider will typically start you at a lower dose of the new medication and re-titrate up, even if you were at the maximum dose of the previous one.

The most common switch direction is Ozempic → Mounjaro, usually because a patient wants more weight loss or has plateaued. Switching from Mounjaro → Ozempic is less common but happens when insurance coverage changes or when a patient wants to transition to the oral option.

If you're considering a switch, bring it up with your provider. The dose titration calculator can help map out what the re-titration timeline looks like on the new medication.

The Brand Name vs Generic Name Confusion

This trips people up constantly, so here's the decoder ring.

Generic Name	Diabetes Brand	Weight Loss Brand	Manufacturer
Semaglutide	Ozempic	Wegovy	Novo Nordisk
Tirzepatide	Mounjaro	Zepbound	Eli Lilly

Ozempic and Wegovy are the same drug (semaglutide) at different doses for different conditions. Mounjaro and Zepbound are the same drug (tirzepatide) at the same doses for different conditions. When people say "Mounjaro vs Ozempic," they're really asking about tirzepatide vs semaglutide — just using brand names because that's what they see on TV and in pharmacy bags.

The GLP-1 medications overview untangles all the brand and generic names if you want the full picture, and our generic-name comparison covers the same clinical data discussed here from a more science-focused angle.

What About Newer Options?

The GLP-1 field is moving fast. A few developments worth knowing about:

Wegovy HD (semaglutide 7.2 mg): Approved March 2026, this higher-dose semaglutide may narrow the gap between the two drugs. The STEP UP trial showed 20.7% average weight loss — close to tirzepatide's SURMOUNT numbers. It's a new option for patients who respond well to semaglutide but want more effect. See the semaglutide dosing chart for details.

Oral Wegovy: Launched January 2026, this is the first oral GLP-1 for weight management. It's semaglutide in pill form — 50 mg daily at maintenance, taken on an empty stomach. No tirzepatide equivalent exists yet. The oral Wegovy guide covers what you need to know.

Retatrutide: Eli Lilly's next-generation drug targets three receptors (GLP-1, GIP, and glucagon) instead of two. Phase 2 trials showed up to 24% weight loss. Still in clinical trials as of early 2026. The retatrutide overview covers the current state of research.

Medicare coverage: As of April 2026, Medicare covers Zepbound for weight management. This is a significant change that affects millions of potential patients who previously had no coverage for these drugs.

Frequently Asked Questions About Mounjaro vs Ozempic

Is Mounjaro more effective than Ozempic for weight loss?

Yes, based on current clinical evidence. The SURMOUNT-5 head-to-head trial showed that tirzepatide (Mounjaro/Zepbound) at maximum dose produced 20.2% body weight loss versus 13.7% for semaglutide (Ozempic/Wegovy) at 72 weeks. Twice as many patients on tirzepatide reached the 25% weight loss threshold. That said, semaglutide is still highly effective — 14% average weight loss is clinically meaningful, and the newer 7.2 mg Wegovy HD dose may produce results closer to tirzepatide.

Which has fewer side effects, Mounjaro or Ozempic?

Both drugs cause similar types of side effects — primarily nausea, diarrhea, constipation, and vomiting. In the SURMOUNT-5 trial, fewer tirzepatide patients discontinued due to side effects (2.7%) compared to semaglutide patients (5.6%). This may reflect tirzepatide's more gradual titration rather than the drug being inherently gentler. Individual experiences vary significantly. The side effects guide covers what GI symptoms to expect and how to manage them.

How much does Mounjaro cost compared to Ozempic in 2026?

At list price, both cost roughly $1,000/month (Mounjaro ~$1,080, Ozempic ~$998). With commercial insurance, co-pays for either typically range from $25-$150/month. Cash-pay pricing varies widely depending on discounts, manufacturer programs, and pharmacy choice. For weight loss specifically (Zepbound vs Wegovy), Medicare began covering Zepbound in April 2026. Use the cost calculator to estimate your specific out-of-pocket cost.

Can I switch from Ozempic to Mounjaro?

Yes. Switching is common and doesn't require a washout period. Your provider will typically start you at a lower tirzepatide dose (usually 2.5 or 5 mg) and re-titrate, even if you were at the maximum semaglutide dose. The most common reason for switching is wanting more weight loss or hitting a plateau. Talk to your provider about whether switching makes sense for your situation — the provider quiz can connect you with someone experienced in managing both medications.

Do Mounjaro and Ozempic work differently?

Yes. Ozempic (semaglutide) activates one hormone receptor — GLP-1. Mounjaro (tirzepatide) activates two — GLP-1 and GIP. This dual mechanism appears to be the reason tirzepatide produces more weight loss in clinical trials. Both reduce appetite, slow stomach emptying, and improve insulin function. Tirzepatide's GIP activation adds additional effects on fat metabolism. The tirzepatide guide explains the dual mechanism in detail.

Is there a pill version of Mounjaro?

No. As of early 2026, tirzepatide is only available as a weekly injection (KwikPen). Semaglutide is the only GLP-1 medication available in both injectable and oral forms. Oral Wegovy (50 mg daily) launched in January 2026 for weight management. If avoiding injections is a priority, semaglutide is currently your only GLP-1 option.

Which should I choose — Mounjaro or Ozempic?

There's no universal answer. If maximum weight loss is your priority and cost isn't a barrier, tirzepatide (Mounjaro/Zepbound) has the stronger clinical data. If your insurance favors one over the other, that often makes the decision. If you want an oral option eventually, semaglutide is the path. The best approach is discussing both options with a provider experienced in prescribing GLP-1 medications. The provider matching quiz can connect you with the right clinician for that conversation.